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In a recent article,1 our group described a role for the circa-
dian protein Rev-erbα in regulating glial activation. We dem-
onstrate time-of-day oscillations in microglial morphology/
activation that are abrogated by the global deletion of Rev-
erbα, which appears to lock microglia in an activated state. 
Transcriptomic changes in the hippocampus of Rev-erbα KO 
(RKO) mice also showed upregulation in inflammatory gene 
expression and activation of pathways associated with inflam-
mation, including the NF-κB pathway. As Rev-erbα is a dedi-
cated transcriptional repressor, we performed ChIP analyses 
and found that Rev-erbα bound to the promoter regions of 
NF-kB-related genes, including TRAF2 and IKBA, and may 
directly regulate NF-kB activation. In vivo, astrocytes are also 
activated in RKO mice. However, whereas RKO primary 
microglia are activated at baseline in vitro, RKO primary 
astrocytes are not. These data suggest a cell-autonomous role for 
Rev-erbα in microglial activation, and a cell non-autonomous 
effect on astrocytes. RKO-mediated neuroinflammation 
resulted in impairments to neuronal health in vitro and on a 
global brain network level. Using the Rev-erb agonist SR9009, 
we showed that the Rev-erb pathway can be targeted to miti-
gate lipopolysaccharide (LPS)-induced neuroinflammation in 
vitro and in vivo. While this article presents all the detrimental 
effects of deleting Rev-erbα, we explored a more nuanced 
view on the results in this commentary.
Rev-erbα has previously been shown to regulate periph-
eral innate immunity.2 Macrophages play a critical role in 
peripheral innate immunity. Given the role of Rev-erbα in 
macrophages, we explored how Rev-erbα could affect micro-
glial function/activation. Classically, macrophage and micro-
glial activation have been classified using the M1/M2 
dichotomy. The M1 state is associated with neurotoxicity, 
whereas the M2 is associated with neurotrophic effects.3 
Recent advances in transcriptomic analyses have challenged 
this classification. Our RKO microglia do not clearly fit into 
either of these categories. On one hand, we noted increases in 
the classical NF-κB signaling cascade that would suggest an 
M1 state. However, our microarray and CD68 staining data 
would suggest increases in phagocytic capacity, which sug-
gests an M2 state. This further illustrates the idea that micro-
glial activation exists on a spectrum and is not so easily 
classified dichotomously. Rev-erbα deletion may induce a 
hybrid activation state that needs to be explored in future 
studies employing microglial-specific transcriptomics. Recent 
work also suggested that activated microglia can induce neu-
rotoxic A1 astrocyte activation.4 Our data indicate that astro-
cyte activation in RKO mice does not fully recapitulate the 
gene expression changes of an A1 or A2 astrocyte activation 
state, although most pan-reactive transcripts are increased. 
Rev-erbα functions as a nuclear receptor and repressor that 
recruits HDAC3 through NCoR.5 The loss of this repressive 
element in the epigenome may prime glia to be more reactive 
to innocuous stimuli, resulting in spontaneous glial activation 
and neuroinflammation.
In addition to their homeostatic functions, microglia have 
recently gained attention for their potential causative role in 
neurodegenerative pathogenesis. Recent genome-wide associ-
ation studies indicated that mutations in microglial and 
phagocytosis genes are highly associated with increased 
Alzheimer disease (AD) risk.6 One of those genes is TREM2, 
which we found to be upregulated in the hippocampus of 
RKO mice. Of note, TREM2 is a damage-associated micro-
glial gene which is upregulated in microglia surrounding amy-
loid plaques.7 Deletion of TREM2 is known to impair 
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microglial responses to amyloid plaques and disrupt microglial 
synapse elimination.
Rev-erbα deletion is also associated with increased microglial 
phagocytic activation—as seen by increased CD68/Iba1 colo-
calization in RKO microglia. Other work has also shown that 
increases in microglial CD68 can result in increased synaptic 
pruning in the hippocampus.8 These suggest that Rev-erbα in 
microglia can potentially regulate synaptic elimination, per-
haps through regulation of TREM2. Although Aβ plaque and 
Tau tangle formation are the classical neuropathological hall-
marks of AD, decline in synaptic health has been found to be 
most closely correlated with cognitive decline.9 Thus, deeper 
understanding of the processes that affect synaptic health is 
critical. Given the increases in phagocytic capacity of RKO 
microglia, it is reasonable to hypothesize a decline in synaptic 
health in AD models lacking Rev-erbα. However, the effects 
may not be so straightforward. Increases in microglial phago-
cytosis can result in reduced Aβ burden in the brain,10 but can 
also exacerbate Tau pathology.11 To fully understand the role 
of Rev-erbα in disease, further studies are necessary. However, 
we speculate that drug interventions through Rev-erbα could 
influence neurodegenerative pathogenesis through modula-
tion of glial function.
Rev-erbα is a heme/lithium sensitive nuclear receptor 
that functions as part of the circadian clock molecular 
machinery.12 Given this, Rev-erb activity can be modulated 
using existing agonists and antagonists, including SR900913 
and SR8278.14 We used SR9009 in vivo and in vitro and 
found that it was effective in mitigating LPS-induced neuro-
inflammation. SR9009 has favorable pharmacokinetics and 
can readily cross the blood brain barrier. However, the 
potency of SR9009 is relatively low, as micromolar quantities 
are required in vitro to exert effects, thus opening the door to 
off-target effects. With regard to suppressing LPS-induced 
inflammation, we observed that the efficacy of SR9009 was 
greatly reduced in RKO mice, suggesting that SR9009 is 
indeed acting through Rev-erbα in this setting. Our data, as 
well as data from other groups,15 provide proof of principle 
that pharmacologic targeting Rev-erbα can mitigate LPS-
induced neuroinflammation and support the development of 
high-affinity agents.
Although results from our group and others15 are encour-
aging, there is a considerable knowledge gap that must be 
addressed before attempting to predict the effect of Rev-erb 
targeted drugs in neurodegenerative diseases. First, LPS-
induced neuroinflammation is very different than the inflam-
mation observed in neurodegenerative diseases. As an 
example, TREM2 is suppressed by LPS, but is upregulated 
by amyloid plaque pathology. Thus, the effects of Rev-erbα 
manipulation will need to be tested in neurodegenerative 
models, as the effects on specific pathways may be quite dif-
ferent. Second, simply reducing neuroinflammation may not 
be enough to ameliorate neurodegenerative sequelae, as glial 
activation can exert differing effects on various aspects of 
pathology at different points in disease course. Using AD as 
an example, inhibiting neuroinflammation through Rev-
erbα activation could abolish the early protective effects pro-
vided by increased phagocytic capacity, as more phagocytic 
microglia could clear plaques and tangles more efficiently 
and delay the onset of neurodegeneration. Conversely, Rev-
erbα activation could provide protection from synapse loss 
later in the disease course. In addition, continuous activa-
tion/blockade of Rev-erbα could be detrimental since our 
data show that microglial activation cycles by time of 
day, and these cycles may be important for normal brain 
homeostasis. Finally, aged microglia are primed and exhibit 
Figure 1. Considerations for the targeting of Rev-erbs in neurodegenerative diseases. Hypothetical model showing the balance between modulating glial 
activation and altering various aspects of neurodegenerative disease. As noted, activation of Rev-erbs could limit glial activation, which might exert 
protective effects of synaptic health, but could exacerbate Aβ and tau accumulation. The effects of Rev-erb may be modulated by circadian influence, as 
well as stage of disease.
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decreased phagocytosis and exaggerated responses to stimuli. 
Therefore, targeting microglial Rev-erbα in aged animals or 
people would further compromise their ability to function as 
phagocytes. This suggests that we would need to consider 2 
axes of time when considering using Rev-erbα—time of day 
and time course of the disease. To fully leverage Rev-erbα as 
a therapeutic target in neurodegenerative disease, all of the 
outlined factors have to be considered. A summary of the 
ideas illustrated is in Figure 1.
Although this commentary begins to consider the potential 
implications of targeting Rev-erbα in neurodegenerative dis-
ease, more in vivo studies are required. On a more fundamental 
level, future studies need to determine the cell type specificity of 
Rev-erbα in mediating neuroinflammation. Our studies were 
done in global RKO mice and could have contributing effects 
from peripheral immune cells or neuronal damage. Future stud-
ies need to parse out the effects of knocking out Rev-erbα in 
only microglia or astrocytes. Regarding the role of Rev-erb in 
neurodegeneration, studies are needed to examine the effect of 
Rev-erbα manipulation, either genetic or pharmacologic, in 
mouse models that address multiple aspects of pathology. 
Finally, the impact of these interventions on cellular circadian 
clocks and sleep cycles will need to be addressed. Although this 
area of investigation is still in its infancy, Rev-erb-targeted 
drugs may present a novel avenue for optimizing glial responses 
in neurodegenerative and other neurological disease.
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